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he Janus Face
f Drug-Eluting Stents*
ames S. Forrester, MD, FACC,
ichael S. Lee, MD, Nikhil Kapoor, MD,
aj R. Makkar, MD
os Angeles, California
anus is the Roman god of gates and doors, of beginnings
nd endings, represented as a double-faced head looking in
pposite directions. In this issue of the Journal, Cho et al.
1) lead us to look both forward and backward as they
ompare the effect of a 6-day course of granulocyte colony
timulating factor (GCSF) on neointimal hyperplasia and
ndothelial healing after vascular injury by bare-metal stent
BMS) and paclitaxel-eluting stent (PES) in the rabbit.
emarkably, the drug had substantially different effects in
he two groups at 2 months. Substantial intimal hyperplasia
nd delayed endothelial recovery occurred in the BMS
roup but not in the PES group. The study bears directly on
wo of the most important yet seemingly unrelated issues in
urrent clinical interventional cardiology research: in-stent
estenosis and myocardial regenerative therapy. To under-
tand how this came to be, we need to revisit the history of
CSF-related cardiovascular research in the past decade.
See page 366
In the late 1990s, GCSF was reported to be effective in
nimal models of therapeutic angiogenesis (2). Intense
nterest in the cardiovascular use of GCSF, however, can
erhaps be traced to late 2001, when two near-simultaneous
ublications showed its efficacy in restoring myocardial
erfusion and function in the rat infarct model. In one
tudy, human bone marrow-derived angioblasts mobilized
y administration of GCSF were delivered via intravenous
njection (3). At 15 weeks, new capillary formation was
hree-fold greater in the treated group than in the control
roup, the number of apoptotic cells was reduced six-fold,
nd infarct size was reduced from 36% to 12%. In the other
tudy, GCSF and rat stem cell factor were given for 8 days
n the peri-infarct period, with the goal of stimulating bone
arrow cells to home to the infarcted myocardium (4). At
month, rat mortality was decreased by 68% , infarct size by
0%, and ejection fraction improved progressively by 48%,
2%, and 114% versus control subjects at 1, 2, and 4 weeks,
espectively. These results were confirmed by other investi-
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles,
alifornia.ators (5,6). Thus, two streams of research flowed together
o create a river of intense pressure for clinical trials in both
yocardial infarction (MI) and stable coronary disease. The
dea had particular appeal, because GCSF had a long prior
ecord of safe and successful use in hematology (7) and in
rinciple it could be given in any hospital. Clinical investi-
ators around the world vied to be the first to report the
esults of cardiovascular GCSF therapy in man.
There were, of course, cautionary theoretical questions
aised. The cytokine cousin of GCSF, granulocyte-
acrophage colony stimulating factor (GMCSF) had been
eported to have adverse effects in the animal model of
nfarction (8). More directly, we speculated that GCSF
ould also have adverse effects in man (9), because increased
eukocyte count is associated with increased risk of mortality
10), acute coronary syndromes are often preceded by
ystemic inflammation (11), and multiple unstable plaques
haracterize acute MI in man (12). Ironically, the first
ata-based cautionary note in man, however, was not an
ncreased incidence of re-infarction. Rather, it was an
ntirely unanticipated complication. In March 2004, Kang
t al. (13) reported the results of randomizing 27 BMS
nfarct patients into treatment, with intracoronary bone
arrow cells mobilized by GCSF infusion (n  10),
-CSF alone (n  10), and 7 control subjects. In the
reated groups, the myocardial perfusion defect diminished
12% vs. 5%) and ejection fraction increased significantly
49% vs. 55%), as predicted by the rat MI studies; but at 6
onth follow-up, 7 of 10 treated patients had in-stent
estenosis, leading to termination of the study. The authors
peculated that “although G-CSF might accelerate growth
f neointima with bare metal stents, it might be beneficial
ith drug-eluting stents in promoting re-endothelialization,
esulting in significant reduction of inflammation and re-
tenosis.” Indeed their speculation seems to have been
roved accurate by the current study.
As other randomized clinical trials continued, however,
he initial dramatic effects of GCSF reported in the rat
nfarct model were not being reproduced in larger animals.
ith the porcine infarct model, other investigative groups,
ncluding our own, found no significant difference in early
r late post-infarction left ventricular ejection fraction
etween G-CSF treated groups and control subjects, despite
ignificant differences in regional myocardial function (14).
Then, in November 2005, the other shoe dropped. Two
andomized clinical trials, both published in the Journal of
he American College of Cardiology, were terminated early
ecause of an increased incidence of acute coronary events in
he treatment group. The first, a multinational trial aimed at
herapeutic revascularization in 16 stable angina patients,
ound that although indices of platelet activation and
oagulation remained unchanged, C-reactive protein nearly
oubled (15). Two patients sustained an MI, one of whom
ied. In the same issue, a Swiss team reported that two of
even stable angina patients given GMCSF sustained an
a
i
T
s
o
a
o
a
G
p
s
o
t
o
p
a
h
t
p
t
i
i
s
i
s
c
b
s
a
t
t
t
l
A
p
p
d
t
s
a
R
D
e
f
R
1
1
1
1
1
1
1
1
1
1
2
376 Forrester et al. JACC Vol. 48, No. 2, 2006
Editorial Comment July 18, 2006:375–6cute coronary syndrome during treatment (16). Editorials
n the Journal of the American College of Cardiology (17) and
he Lancet (18) concluded that GCSF and GMCSF trials
hould be restricted to patients with no other therapeutic
ptions. In sum, it now seems unlikely that systemic
dministration of GCSF will find a role in the management
f either stable coronary disease or acute MI. In retrospect,
nimal laboratory studies failed to test whether systemic
CSF increased either the risk of in-stent restenosis or
laque destabilization before initiation of clinical trials.
With the future of cardiovascular GCSF therapy so
eriously in question, it might seem surprising that a study
f systemic GCSF therapy in rabbits provides both impor-
ant insight and new directions for interventional cardiol-
gy. The study of Cho et al. (1), however, provides a
rovocative new idea: the processes of intimal hyperplasia
nd endothelial healing can be separated. The authors
ypothesize—and their results strongly support—the idea
hat paclitaxel inhibited intimal hyperplasia, whereas GCSF
romoted endothelial healing. This important insight seems
o provide a foundation for the ultimate solution to stent-
ng’s most important limitations: intimal hyperplasia and
mpaired endothelial healing, the proximate causes of in-
tent restenosis and late stent thrombosis, respectively. The
ssue of impaired endothelial healing with drug-eluting
tents is paramount, because in a recent report of 2,229
onsecutive patients, 29 (1.3%) patients had stent throm-
osis (1.7% of PES), of whom 45% died (19). We might
peculate that local delivery and timing of process-specific
gents will be critical components of the solution to these
wo problems. As if on cue, in the past year the capacity to
est this hypothesis became available through third genera-
ion stents that can deliver several different substances
ocally at predetermined times after stent implantation (20).
s we look to the future, it might be that GCSF and even
aclitaxel will be only historical signposts, whereas the
hysiologic processes exposed by the Cho et al. (1) study,
riven by the failure of past clinical trials, will be central to
hat final resolution. Such is the wonderful illogic of
cientific progress, in which the past is prologue and failures
re sometimes more important than successes.
eprint requests and correspondence: Dr. James S. Forrester,
ivision of Cardiology, Cedars-Sinai Medical Center, 8700 Bev-
rly Boulevard, Los Angeles, California 90048. E-mail:
orrester@cshs.org.
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